Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Liver Neoplasms 4Carcinoma, Hepatocellular 4Neoplasm Metastasis 3Biliary Tract Neoplasms 2Thyroid Cancer, Papillary 1Rectal Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Bile Duct Neoplasms 1Barrett Esophagus 1Adenocarcinoma Of Esophagus 1

Interventions

Paclitaxel 6Radiotherapy 5Fluorouracil 5Cisplatin 4Taxes 3Specimen Handling 3Radiation 2Erlotinib Hydrochloride 2Endoscopy, Digestive System 2Endoscopy 2trastuzumab biosimilar HLX02 1rubitecan 1romidepsin 1oblimersen 1obeticholic acid 1cixutumumab 1bryostatin 1 1alvocidib 1adavosertib 1Trastuzumab 1Ramucirumab 1Radiofrequency Ablation 1PF-05280014 1Oxaliplatin 1Ontruzant 1Ogivri 1Nivolumab 1Neoadjuvant Therapy 1Microarray Analysis 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Adenocarcinoma Of Esophagus × Radiofrequency Ablation × Clear all
NCT06732388 2026-05-13

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
64 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡